Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01231269 | Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma | unknown | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02661503 | HD21 for Advanced Stages | unknown | Phase 3 | 1,500 | University of CologneOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT03337919 | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma(ANIMATE) | unknown | Phase 2 | 78 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06363201 | Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | unknown | N/A | 40 | Catalysis SLINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06340243 | Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt | unknown | — | 50 | Assiut UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | unknown | Phase 1 / Phase 2 | 41 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04776265 | RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT | unknown | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04090268 | Precision Exercise in Children With Malignant Hemopathies(SportTherapy) | unknown | N/A | 380 | University of Milano BicoccaOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03617666 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study(AVENuE) | unknown | Phase 2 | 49 | University College, LondonOTHER | 2 | Dec 12, 2023 | clinicaltrials |
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma(PLIMATH) | unknown | Phase 2 | 27 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Aug 21, 2023 | clinicaltrials |
| NCT05900765 | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05490953 | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma | unknown | Phase 4 | 30 | University of GuadalajaraOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05663983 | Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients | unknown | — | 600 | Campus Bio-Medico UniversityOTHER | 0 | Dec 23, 2022 | clinicaltrials |
| NCT05660993 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | unknown | Phase 2 | 50 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05254821 | Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients | unknown | — | 130 | Federico II UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03552003 | Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | unknown | — | 400 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518318 | GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) | unknown | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 0 | Aug 26, 2022 | clinicaltrials |
| NCT02589548 | Brazilian Prospective Hodgkin Lymphoma Registry | unknown | — | 1,400 | Universidade Federal do Rio de JaneiroOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | unknown | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05284396 | Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 17, 2022 | clinicaltrials |
| NCT04893538 | Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma | unknown | — | 100 | Latakia UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT03374007 | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma(GB226) | unknown | Phase 1 | 72 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04866654 | Radiation Free Chemotherapy for Early Hodgkin Lymphoma(RAFTING) | unknown | Phase 2 | 160 | Medical University of GdanskOTHER | 3 | Aug 12, 2021 | clinicaltrials |
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04665063 | A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04419441 | Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma(ICI-RT-1) | unknown | — | 12 | Ospedale Maggiore Di TriesteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | unknown | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | unknown | Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03474133 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)(BASALT) | unknown | Phase 2 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | unknown | — | 120 | Marco PicardiOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03260101 | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | unknown | — | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2024source: clinicaltrials